Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 4Phase 3 3Phase 1 2

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 127Breast Neoplasms 127Ovarian Neoplasms 79Fallopian Tube Neoplasms 45Lung Neoplasms 42Carcinoma, Ovarian Epithelial 30Uterine Cervical Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 27Endometrial Neoplasms 25Triple Negative Breast Neoplasms 23Neoplasms 20Neoplasm Metastasis 20Esophageal Neoplasms 19Stomach Neoplasms 18Esophageal Squamous Cell Carcinoma 14Adenocarcinoma of Lung 13Carcinoma 12Brenner Tumor 11Recurrence 10Urinary Bladder Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Peritoneal Neoplasms 7Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma, Bronchiolo-Alveolar 5Adenocarcinoma 5Melanoma 4Carcinoma, Ductal, Breast 4Adenocarcinoma Of Esophagus 4

Interventions

Gemcitabine 12Mitomycin 11Cisplatin 10Carboplatin 8pembrolizumab 7Docetaxel 4toripalimab 3avelumab 3atezolizumab 3Paclitaxel 3sacituzumab govitecan 2disitamab vedotin 2Taxes 2Specimen Handling 2Platinum 2Magnetic Resonance Spectroscopy 2Injections 21,2-diaminocyclohexaneplatinum II citrate 2vinflunine 1valrubicin 1tislelizumab 1lenvatinib 1eribulin 1epacadostat 1enfortumab vedotin 1durvalumab 1dodecyl maltoside 1Vitamin B 12 1Standard of Care 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Transitional Cell × Paclitaxel × Clear all
NCT06524544 2026-05-27

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
320 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT04579224 2026-05-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
184 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06857175 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
508 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡